Lumakras Sales A Highlight Of Amgen’s Mixed Q3
Aimovig Down Sequentially And Year-Over-Year
Executive Summary
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.